MedPath

Milk Protein and Bone Health in Postmenopausal Women

Not Applicable
Completed
Conditions
Bone and Bones
Osteoporosis Risk
Osteoporosis, Postmenopausal
Interventions
Dietary Supplement: Milk-based protein matrix (MBPM)
Dietary Supplement: Habitual dietary behaviour
Registration Number
NCT03701113
Lead Sponsor
University of Limerick
Brief Summary

The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone health. A balanced rate of bone resorption is required to maintain bone health, a balance that can be disturbed during the life-cycle to effect net rate of formation (as occurs during growth and development to adulthood) or net resorption (as occurs, for example, during the menopause). Bone turnover is a nutritionally modulated process and the investigators believe a milk-based protein supplement (MBPS) can modulate beneficially the rate of bone resorption over the time period when bone remodeling is most active i.e. late evening/overnight. In this novel approach to the timing of nutrient ingestion, the proposed nutrient intervention seeks to modify (reduce) the rate of bone resorption and promote the rate of bone formation to the benefit of bone health in this at risk population..

Detailed Description

Study design:

A block randomised, controlled study among healthy, post-menopausal women with osteopenia receiving a milk-based protein supplement (MBPS) in the evening, or not,(CONTROL) for a period of 24 weeks.

Composition of MBPM - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured. All formulations to be supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.

Participants:

60 Post-menopausal women with osteopenia as determined by site-specific bone mineral density BMD (DXA) diagnosed and screened by a clinician and for dietary intake of calcium and Vit D by a clinical dietitian.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
64
Inclusion Criteria
  • Post-menopausal women aged 50-70y. Assessed by site-specific BMD to be osteopenic. Assessed by clinical screen to be otherwise healthy and free from other illness or current medication likely to influence the study outcome.
Exclusion Criteria
  • Intolerance to dairy-based food products

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Milk-based protein matrix (MBPM)Milk-based protein matrix (MBPM)Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
CONTROLHabitual dietary behaviourIntervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
Primary Outcome Measures
NameTimeMethod
Aerial Bone Mineral Density (BMD)Change from Baseline BMD at 24 weeks

Site specific (hip and lumbar) BMD measured by Dual Energy X-ray Absorptiometry (DXA)

Secondary Outcome Measures
NameTimeMethod
Bone ResorptionChange from Baseline CTX, NTX and DPD at 24 weeks

Measured by biomarkers of bone resorption in fasting blood, i.e. C-terminal telopeptide of type I collagen (CTX, ng/ml), and diurnal (24h) urinary deoxypyridinoline (DPD, nmol/mmol creatinine) and N-terminal telopeptide of type I collagen (NTX, nmol/mmol creatinine) excretion normalised for urinary creatinine.

Bone FormationChange from Baseline P1NP at 24 weeks

Measured by a biomarker of bone formation in fasting blood, i.e. serum pro-collagen type 1 N-terminal propeptide (P1NP, ng/ml)

Trial Locations

Locations (1)

University of Limerick

🇮🇪

Limerick, Ireland

© Copyright 2025. All Rights Reserved by MedPath